CBIO GLYCOMIMETICS INC Insider Trading

Fairmount Funds director acquired 1,360,000 shares of CBIO for $18.2M, doubling stake to 2.75M shares

Fairmount Funds Management LLC executed a substantial $18,237,600.00 open-market purchase of 1,360,000 shares at $13.41 on 2025-12-04, increasing its holdings by 98.0%. However, the transaction's significance is substantially dampened by both company fundamentals and the insider's prior cross-ticker track record. Crescent BioPharm generated only $75,000.00 in latest quarterly revenue and posted a net income of $-24,607,000.00, with annual revenue declining 86.7% year-over-year; the company remains unprofitable. Fairmount's cross-ticker buy history shows mixed performance: 14 prior buys averaged +16.3% over 30 days but only -8.0% over 90 days, with a 33.33% win rate at the 90-day mark. The stock currently trades at $13.17, down 26.8% from its 52-week high and barely changed on a 30-day basis (+0.3%), providing limited near-term validation of this large accumulation.

CMO Rock Edwin buys 305,000 GLYC shares in 2 transactions (June 20-21) at $0.26 blended avg, stock down 90.6% in 90 days

Rock Edwin, Chief Medical Officer of GlycoMimetics, purchased 305,000 shares across two separate transactions on June 20-21, 2024, for a combined $78,824.50 at a blended average price of $0.26, expanding his holdings by 81.2%. This comes against a backdrop of severe deterioration: the stock has declined 90.6% over the past 90 days and currently trades at $26.66, down 92.4% from its 52-week high of $349.00. Fundamental conditions are dire, with the company reporting quarterly revenue of $75,000.00 while generating a net loss of $10,736,667.00, and annual revenue contracted 86.7% year-over-year. Notably, Edwin's own prior transaction history at this ticker shows he bought twice in September 2023, both timing well at the 90-day horizon with gains exceeding 9000%, suggesting an established pattern of accumulation at depressed moments; however, his current purchase occurs against far steeper recent losses and into a company with severe revenue collapse and persistent unprofitability, presenting a markedly different risk context than his prior buys.

CFO Hahn buys 17,500 shares of GLYC at $0.25; stock down 92.8% from $349.00 high, revenue collapsed 86.7% YoY.

Brian M. Hahn, SVP Finance and CFO, purchased 17,500 shares at $0.25 on 2024-06-18, increasing his holdings by 32.9% to 70,643 shares post-transaction. This buy occurs at an extreme valuation nadir: the stock has fallen 92.8% from its 52-week high of $349.00, while the company's fundamentals have deteriorated sharply—annual revenue declined 86.7% and the latest quarter generated only $75,000 in revenue against a net loss of $-10.7M. The CFO's purchase of 17,500 shares at these depressed levels, despite the company's unprofitability and collapsing top line, warrants scrutiny regarding management's assessment of intrinsic value recovery versus market perception of the company's viability. The magnitude of the price decline (92.8%), combined with the severity of operational contraction (86.7% revenue drop), indicates a high-risk inflection point that investors should monitor closely.